If you think that the CEO of Starpharma Jackie Fairley will announce full results of any in-house DEP trials to the ASX by the end of June ~ I have a monorail to sell you.
If you think that the CEO of Starpharma Jackie Fairley will announce a big pharma partner to take any in-house DEP drugs into Phase 3 to the ASX by the end of June ~ I have a TWO monorails to sell you.
I cannot see any positive catalysts of substance before the EOFY. All that you can pretty much bank on regarding the share price IMO is tax loss selling (the SP was $1.53 on 1st July 2021) and instos likely lightening ahead of Starpharma’s expected falling from relevance and out of the ASX300 in the September rebalance.
All IMO only. Please DYOR.
SPL Price at posting:
72.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)